BAG2-mediated mutant p53 aggregation inhibits the mitochondrial apoptosis pathway, leading to chemoresistance in breast cancer cells, and HSP90 inhibitor (IPI-504) can relieve BAG2-mediated mutant p53 aggregation [17]. This evidence concerns the gene BAG2 and breast carcinoma.